hip hip horay !, page-8

G'day again tuggeranong,

I am sure YOU are aware but just so that anybody reading this does not get the wrong picture - the Cepheid test is for ACTIVE TB not LATENT TB. It cannot therefore be compared to QFT and is definitely NOT a competitor to QFT.

The above FACT therefore makes your comments about cost comparison totally moot.

As to WHEN the price will rise to $3 that is not up to me. I am a mere holder of CST stock. YOU, on the other hand, could buy back in and thereby impact the share price. :)

As to sales progression. We might have a better idea in a couple of weeks when the HY report is released. In the meantime, a small amount of searching will find much discussion and data that has been presented by myself and others.